Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01873885 · ClinicalTrials.gov registry record · Phase 1
Phase 1, Randomized, Double-Blind, Placebo-Controlled Exploratory Study That Will Assess the Safety, Tolerability, Pharmacokinetics and Hemodynamic Response to a Single 30 Minute Intravenous Infusion of Vasomera™ (PB1046) in Adult Subjects With Stage 1 or 2 Essential Hypertension
A Phase 1 study, sponsored by PhaseBio Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
NCT01873885 is a Phase 1 study that has completed, run by PhaseBio Pharmaceuticals. The registered enrollment target is 20 participants.
The verdict
NCT01873885, a Phase 1 study, has completed, sponsored by PhaseBio Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
Study Summary
This study is an exploratory Phase 1 randomized, double-blind (Investigator and study subject and 2-D echo endpoint assessor), placebo-controlled single IV infusion dose escalation study that will enroll up to approximately 32 subjects with stage 1 or 2 essential hypertension.
Interventions
- DRUG Placebo Single IV (Intravenous) Infusion
- DRUG Experimental: Single IV Infusion Vasomera (PB1046)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2013-06 |
| Est. Completion | 2014-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01873885
The ClinicalTrials.gov registry entry for NCT01873885 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is PhaseBio Pharmaceuticals, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo Single IV (Intravenous) Infusion is the first listed.
NCT01873885 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01873885 about?
NCT01873885 is a clinical study titled "Phase 1, Randomized, Double-Blind, Placebo-Controlled Exploratory Study That Will Assess the Safety, Tolerability, Pharmacokinetics and Hemodynamic Response to a Single 30 Minute Intravenous Infusion of Vasomera™ (PB1046) in Adult Subjects With Stage 1 or 2 Essential Hypertension". This study is an exploratory Phase 1 randomized, double-blind (Investigator and study subject and 2-D echo endpoint assessor), placebo-controlled single IV infusion dose escalation study that will enroll up to approximately 32 subjects with stage 1 or 2 essential hypertension.
What is the current status of trial NCT01873885?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2013-06. Estimated completion is 2014-03.
What interventions are being tested in trial NCT01873885?
The interventions under investigation include: Placebo Single IV (Intravenous) Infusion (DRUG), Experimental: Single IV Infusion Vasomera (PB1046) (DRUG).
Who is sponsoring clinical trial NCT01873885?
This trial is sponsored by PhaseBio Pharmaceuticals, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.